Moreover, the metastatic signatures combined with serum CEA (≥5 ng/ml) improved the sensitivity by 24.8% (82.9% vs. 58.1%) for metastatic CRC patients compared with CEA alone. Here, CEACAM5 is linked to colorectal carcinoma.